https://www.selleckchem.com/pr....oducts/rg2833-rgfp10
Detailed CMV kinetics in donor CMV-seropositive, recipient CMV-seronegative (D+R-) transplant recipients receiving preemptive therapy (PET) have not been fully defined. The study population consisted of PET arm of a randomized CMV prevention trial in D+R- liver transplant recipients. CMV-DNA PCR assays were performed weekly for 100 days using a sensitive assay. Viral load and clinical parameters were compared for patients with or without high-level increase (defined as higher than the group median log10 increase in viral load fro
Like
Comment
Share
